Abstract
The intrastriatal perfusion of the selective metabotropic glutamate (mGlu)5 receptor agonist (RS)-2-chloro-5-hydroxy-phenylglycine (CHPG, 1000 microM) significantly increased (approximately + 100%, p < 0.05) glutamate extracellular levels with respect to basal values. The potentiating effect of CHPG was prevented by the selective mGlu5 receptor antagonist 2-methyl-6(phenyl-ethynyl)-pyridine (MPEP, 250 microM)) and by the adenosine A2A receptor antagonist SCH 58261 (2 mg/kg, i.p.). The results show that mGlu5 receptors are involved in the regulation of striatal glutamate release and suggest an involvement of adenosine A2A receptors in mGlu5 receptor-mediated effects.
MeSH terms
-
Animals
-
Corpus Striatum / drug effects
-
Corpus Striatum / metabolism*
-
Excitatory Amino Acid Antagonists / pharmacology
-
Glutamic Acid / metabolism*
-
Glycine / analogs & derivatives*
-
Glycine / pharmacology
-
Male
-
Microdialysis
-
Neuroprotective Agents / pharmacology
-
Phenylacetates / pharmacology*
-
Pyridines / pharmacology
-
Pyrimidines / pharmacology
-
Rats
-
Rats, Sprague-Dawley
-
Receptor, Metabotropic Glutamate 5
-
Receptors, Metabotropic Glutamate / agonists*
-
Receptors, Metabotropic Glutamate / antagonists & inhibitors
-
Receptors, Purinergic P1 / drug effects
-
Receptors, Purinergic P1 / physiology*
-
Triazoles / pharmacology
Substances
-
2-chloro-5-hydroxyphenylglycine
-
5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine
-
Excitatory Amino Acid Antagonists
-
Neuroprotective Agents
-
Phenylacetates
-
Pyridines
-
Pyrimidines
-
Receptor, Metabotropic Glutamate 5
-
Receptors, Metabotropic Glutamate
-
Receptors, Purinergic P1
-
Triazoles
-
Glutamic Acid
-
6-methyl-2-(phenylethynyl)pyridine
-
Glycine